iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

iOnctura Netherlands United States of America United Kingdom Switzerland California

Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investorsTo progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancersTo accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indicationsView original content:https://www.prnewswire.co.uk/news-releases/ionctura-announces-eur80-million-series-b-financing-to-progress-pipeline-through-phase-ii-trials-302176882.html